Earnings summaries and quarterly performance for DYNAVAX TECHNOLOGIES.
Research analysts who have asked questions during DYNAVAX TECHNOLOGIES earnings calls.
Jonathan Miller
Evercore ISI
4 questions for DVAX
Also covers: APLS, ARVN, ATRA +8 more
Matthew Phipps
William Blair
4 questions for DVAX
Also covers: ABBV, AGEN, AMGN +8 more
RB
Roy Buchanan
Citizens JMP
4 questions for DVAX
Also covers: ABUS, CDTX, CVAC +5 more
PN
Philip Nadeau
TD Cowen
3 questions for DVAX
Also covers: ADVM, APLS, ATRA +13 more
PC
Paul Choi
Goldman Sachs
2 questions for DVAX
Also covers: AMRN, ARVN, ASND +12 more
EW
Edward White
H.C. Wainwright & Co.
1 question for DVAX
Also covers: CRIS, GLYC, IKT +5 more
ER
Ernesto Rodriguez-Dumont
TD Cowen
1 question for DVAX
Also covers: KURA, TBPH
KC
Kyuwon Choi
Goldman Sachs
1 question for DVAX
Also covers: AMRN, ASND, BHVN +9 more
Recent press releases and 8-K filings for DVAX.
Dynavax Technologies Corporation to be Acquired by Sanofi
DVAX
M&A
Takeover Bid
- Sanofi has entered into an agreement to acquire Dynavax Technologies Corporation for $15.50 per share in cash, reflecting a total equity value of approximately $2.2 billion.
- The offer price represents a premium of approximately 39% over Dynavax's closing share price on December 23, 2025.
- Dynavax's board of directors has unanimously approved the transaction, which includes Dynavax's marketed adult hepatitis B vaccine (HEPLISAV-B®) and a Phase 1/2 shingles vaccine candidate (Z-1018).
Dec 29, 2025, 12:31 PM
Sanofi Agrees to Acquire Dynavax for $2.2 Billion
DVAX
M&A
Takeover Bid
- Sanofi has agreed to acquire Dynavax Technologies for $15.50 per share in cash, valuing the company at approximately $2.2 billion.
- This acquisition represents a 39% premium to Dynavax's recent trading and a 46% premium over its three-month volume-weighted average price.
- The deal will add Dynavax's marketed adult hepatitis B vaccine HEPLISAV-B and the Phase 1/2 shingles candidate Z-1018 to Sanofi’s adult immunization portfolio.
- Sanofi expects the transaction to close in the first quarter of 2026 and does not anticipate it will affect its 2025 financial guidance.
- The acquisition aims to expand Sanofi’s global reach and accelerate the development and distribution of Dynavax’s vaccine pipeline.
Dec 24, 2025, 6:33 AM
Dynavax to be Acquired by Sanofi
DVAX
M&A
Takeover Bid
- Sanofi announced an agreement to acquire Dynavax Technologies Corporation for $15.50 per share in cash, reflecting a total equity value of approximately $2.2 billion.
- The offer price represents a 39% premium over Dynavax's closing share price on December 23, 2025, and a 46% premium over its 3-month volume-weighted average price as of the same date.
- The acquisition will augment Sanofi's adult immunization presence by adding Dynavax's marketed adult hepatitis B vaccine, HEPLISAV-B®, and its phase 1/2 shingles vaccine candidate, Z-1018, to Sanofi's portfolio.
- The transaction has been unanimously approved by the Dynavax board of directors and is expected to close in the first quarter of 2026, subject to customary closing conditions.
Dec 24, 2025, 6:23 AM
Sanofi to acquire Dynavax
DVAX
M&A
Takeover Bid
- Sanofi has entered into an agreement to acquire Dynavax Technologies Corporation for $15.50 per share in cash, reflecting a total equity value of approximately $2.2 billion.
- The acquisition will add Dynavax's marketed adult hepatitis B vaccine, HEPLISAV-B, and its phase 1/2 shingles vaccine candidate, Z-1018, to Sanofi's portfolio, enhancing Sanofi’s presence in adult immunization.
- The transaction has been unanimously approved by the Dynavax board of directors and is expected to close in the first quarter of 2026.
Dec 24, 2025, 6:15 AM
Dynavax Discusses HEPLISAV-B Market Share, Oral COVID Vaccine, and Pipeline Progress
DVAX
Guidance Update
New Projects/Investments
M&A
- Dynavax reiterated its long-term guidance for HEPLISAV-B, targeting 60% market share of a market projected to grow to over $900 million by 2030, with current retail segment share at 63% and a goal of over 75% in retail over time.
- The company acquired an oral COVID vaccine from Vaxart, emphasizing the pursuit of a differentiated product with a novel mechanism of action to address the multi-billion dollar market, particularly for high-risk patients. The deal structure provides optionality to evaluate top-line data before committing to costly Phase 3 development, balancing risk and opportunity.
- Dynavax is also advancing its shingles vaccine program, expecting a significant ex-US prevalence market and a US market focused on the aging population, alongside a pandemic flu vaccine program with potential for a single-dose option.
Dec 2, 2025, 7:10 PM
Dynavax Discusses HEPLISAV-B Market Share, Oral COVID Vaccine Strategy, and Pipeline Updates
DVAX
Guidance Update
M&A
New Projects/Investments
- Dynavax aims for 60% market share for HEPLISAV-B in a market projected to exceed $900 million by 2030, driven by a shift to retail settings where they currently hold 63% share and target over 75% long-term.
- The company recently acquired an oral COVID vaccine from Vaxart, emphasizing its differentiated mucosal mechanism of action and potential to address high-risk populations, with an efficacy data readout expected to be a "true proof of concept".
- Dynavax sees a significant opportunity in the shingles vaccine market, particularly in the U.S. aging cohort and potentially a future booster market, noting strong commercial synergy with HEPLISAV-B due to shared retail pharmacy distribution.
- Upcoming data for the shingles Part 2 study (70+ population) will focus on vaccine response rate and tolerability, while top-line safety and immunogenicity data for the pandemic flu program are also expected next year.
Dec 2, 2025, 7:10 PM
Dynavax Discusses Hep B Market, Oral COVID Vaccine Acquisition, and Pipeline Updates
DVAX
Guidance Update
New Projects/Investments
M&A
- Dynavax maintains its long-term guidance for HEPLISAV-B, aiming for 60% market share by 2030 in a market projected to exceed $900 million, with a current retail share of 63% and a target of over 75% in the retail setting over time.
- The company acquired Vaxart's oral COVID vaccine program, with a strategy to develop a differentiated product offering a fundamentally different mechanism of action and improved efficacy, rather than a "me-too" product.
- Dynavax is developing a shingles vaccine, with a potential launch in the early 2030s, and is open to partnerships to share development risk and address ex-U.S. opportunities.
- Top-line safety and immunogenicity data for the part two study of its pandemic flu vaccine program are expected next year, with potential for a single-dose option.
Dec 2, 2025, 7:10 PM
Dynavax Announces Q3 2025 Results and Financial Guidance Update
DVAX
Earnings
Guidance Update
Share Buyback
- Dynavax reported HEPLISAV-B net product revenue of $90 million in Q3 2025, marking a 13% increase year-over-year compared to Q3 2024, with its total U.S. market share reaching 46%.
- The company raised its FY 2025 Adjusted EBITDA guidance to ≥$80 million from the previous ≥$75 million.
- Dynavax's Board of Directors authorized a new share repurchase of up to $100 million, bringing the total aggregate share repurchases authorized since November 2024 to ~$300 million.
- As of September 30, 2025, cash, cash equivalents, and marketable securities totaled ~$648 million.
- Key pipeline advancements include positive Part 1 topline results for the Shingles vaccine program and ~$14 million in additional funding from the U.S. DoD for the Plague vaccine program, bringing its total funding to ~$44 million through 1H 2027.
Nov 5, 2025, 9:30 PM
Dynavax Reports Strong Q3 2025 Results, Raises Guidance, and Authorizes Share Repurchase
DVAX
Earnings
Guidance Update
Share Buyback
- Dynavax reported Q3 2025 net product revenue of $90 million for Heplisav-B, a 13% increase year-over-year, contributing to total revenues of $95 million, an 18% increase year-over-year. The company's U.S. adult hepatitis B vaccine market share reached 46%, with retail segment share growing to 63%.
- GAAP net income for Q3 2025 was $27 million, and non-GAAP adjusted EBITDA improved to $36 million. Dynavax reiterated its full-year 2025 Heplisav-B net product revenue guidance of $315-$325 million and raised its adjusted EBITDA guidance to at least $80 million.
- The company authorized a new $100 million share repurchase program and entered into an exclusive license agreement with Vaxart for an oral COVID-19 vaccine program, involving a $25 million upfront payment.
- Key pipeline advancements include the shingles vaccine program entering Part 2 of its Phase 1-2 study, a $14 million Department of Defense award for the plague vaccine candidate, and completion of Part 1 of the pandemic influenza adjuvant program's Phase 1-2 study.
Nov 5, 2025, 9:30 PM
Dynavax Reports Q3 2025 Financial Results and Authorizes New Share Repurchase Program
DVAX
Earnings
Share Buyback
New Projects/Investments
- Dynavax reported total revenues of $94.9 million for Q3 2025, an 18% increase year-over-year, with HEPLISAV-B net product revenue reaching $90.0 million, a 13% increase compared to Q3 2024.
- The company's GAAP net income for Q3 2025 was $26.9 million, or $0.21 diluted earnings per share, and Adjusted EBITDA was $35.5 million.
- Dynavax's Board of Directors authorized a new $100 million share repurchase program.
- The company reiterated its full-year 2025 HEPLISAV-B net product revenue guidance of $315 million to $325 million and increased its Adjusted EBITDA guidance to at least $80 million.
- Dynavax entered into an exclusive license agreement with Vaxart for worldwide rights to Vaxart’s oral COVID-19 vaccine program, which includes an upfront license fee of $25 million and a $5 million equity investment.
Nov 5, 2025, 9:02 PM
Fintool News
In-depth analysis and coverage of DYNAVAX TECHNOLOGIES.
Quarterly earnings call transcripts for DYNAVAX TECHNOLOGIES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more